ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2642

Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy

Norman B. Gaylis1, Joanne Sagliani1, Danny Tuccitto2, Shawn Black3, Kehzen Tang4, Raphael Dehoratius3,5 and Dennis Parenti3, 1Arthritis & Rheumatic Disease Specialties, Aventura, FL, 2AARDS Research, Inc, Aventura, FL, 3Janssen Scientific Affairs, LLC, Horsham, PA, 4Janssen Research & Development, LLC, Spring House, PA, 5Kimmel School of Medicine, Thomas Jefferson University, Philadelphia, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologics, infusions, patient-reported outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient-reported
outcomes (PRO) are used to assess patient related benefit in clinical trials. Rheumatoid
arthritis (RA) patients are equally receptive to intravenous (IV) or
subcutaneous (SC) biologic treatment1. The objective of this study was
to obtain PRO data to understand characteristics of patients who receive IV
biologic agents for RA.

Methods: This was a questionnaire-based
study conducted at a single rheumatology practice with extensive clinical trial
experience.  A total of 100 patients will be enrolled; 87 patients are included
in this interim analysis. The inclusion criteria were: a diagnosis of RA with
IV biologic use for ≥3 mo; ≥18 yrs age; able to read, write and
speak English, willing to complete the questionnaire and a signed informed
consent form. IV biologic treatment was per clinical practice; there were no
treatment assignments and study drug was not supplied. The questionnaire had 30
questions; patients completed the questionnaire prior to receiving a regularly
scheduled dose of IV biologic. Data collected 1-2Q2015.

Results: The mean (±SD) age of patients in
this interim analysis was 57.9 (±14.5) yrs with a mean disease duration of 10.6
(±8.5) yrs (range 0.7-45 yrs). Patients were Caucasian (36.8%), African
American (28.7%), Latino/Hispanic (20.7%), Asian/Pacific Islander (1.1%) and 12.6%
not identified. IV biologics used were infliximab (68%), rituximab (13%), tocilizumab
(10%), abatacept (7%), golimumab (1%) and other (1%).  The mean duration of current
IV therapy was 4.0 (±3.2) yrs (range 0.1 to 16.0 yrs).  Patients’ favorability (1=Not
Favorable, 5=Very favorable) perception of IV therapy BEFORE and AFTER starting
IV therapy is shown in Figures A and B. Amongst all
patients (A), “Very Favorable” increased (p<0.05) from 31% to 65% after
receiving IV therapy; the increase in “Very Favorable” was evident in patients with
or without previous SC therapy (B). 

The favorability scores (mean ±SD) of current IV
therapies were: infliximab 4.7 (±0.6), abatacept 4.7 (±0.5), rituximab 4.3 (±1.0),
golimumab 5 (n=1) and tocilizumab 3.9 (±1.5). Prior SC biologic users had similar
responses to questions identifying advantages or disadvantages associated with
receiving IV biologic therapy as those patients who were not previous SC
biologic users.

Conclusion:   These interim results suggest that among patients
receiving IV biologic therapy for treatment of RA, there is a high degree of
patient satisfaction, including a similar favorability perception of IV therapy
among patients who switched from an SC to an IV biologic.  Our results support
the concept that when there is a shared decision making discussion with
patients regarding biologic treatments, the option of IV therapies should be an
essential part of that discussion and that the RA patient’s perspective should be given meaningful consideration.

1Bolge SC et al Arthritis Rheum 2013;65
Suppl 10:1023


Disclosure: N. B. Gaylis, Janssen Scientific Affairs, LLC, 2; J. Sagliani, Janssen Scientific Affairs, LLC, 2; D. Tuccitto, Janssen Scientific Affairs, LLC, 2; S. Black, Janssen Scientific Affairs, LLC, 3; K. Tang, Janssen R & D, LLC, 3; R. Dehoratius, Janssen Scientific Affairs, LLC, 3; D. Parenti, Janssen Scientific Affairs, LLC, 3.

To cite this abstract in AMA style:

Gaylis NB, Sagliani J, Tuccitto D, Black S, Tang K, Dehoratius R, Parenti D. Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcome-assessment-of-rheumatoid-arthritis-patients-experience-with-iv-administered-biologic-therapy/. Accessed January 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcome-assessment-of-rheumatoid-arthritis-patients-experience-with-iv-administered-biologic-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.